Clinical trials: Inoperable Disease
Hepatocellular Carcinoma
SBRT and Durvalumab for Inoperable/Unresectable Hepatocellular Carcinoma
The investigators propose a phase II single-arm study on using stereotactic body radiation therapy in combination with durvalumab for inoperable/unresectable hepatocellular carcinoma.
- Trial name
- NCT04913480
- Testing
- Durvalumab, Stereotactic body radiation therapy
- Where
- Hong Kong
- Volunteers
- 37 people
- Sponsor
- The University of Hong Kong
Carcinoma, Non-Small-Cell Lung
Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer
The purpose of this study is to determine whether treatment with carboplatin and gemcitabine combined with bevacizumab every two weeks will provide increased survival.
- Trial name
- NCT00400803
- Testing
- Gemcitabine, Carboplatin, Bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Advanced Basal Cell Carcinoma (BCC), Inoperable Disease
Treatment of Basal Cell Carcinoma (BCC) of the Skin, of the Morpheiform, Infiltrative, and Noduloulcerative Types in Inoperable Patients and Not Suitable for Radiotherapy Using Formulated Methylene Blue
The goal of this clinical trial is to evaluate whether formulated methylene blue can safely and effectively treat advanced or inoperable basal cell carcinoma (BCC), a common type of skin cancer.
- Conditions
- Advanced Basal Cell Carcinoma (BCC), Inoperable Disease, Morpheaform Basal Cell Carcinoma, Noduloulcerative Basal Cell Carcinoma
- Trial name
- NCT07311070
- Testing
- Formulated Topical Methylene Blue (0.5 mg/mL), Wound Healing Gel
- Where
- Iran
- Volunteers
- 20 people
- Sponsor
- Daryoush Hamidi Alamdari, PhD
Lung Cancer
Study of Blood and Tissue Samples in Predicting Response to Second-Line Therapy Using Erlotinib Hydrochloride or Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer
RATIONALE: Studying the proteins expressed in samples of blood and tissue from patients with cancer may help doctors identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.
- Trial name
- NCT00989690
- Testing
- docetaxel, erlotinib hydrochloride, pemetrexed disodium
- Where
- Italy
- Volunteers
- 275 people
- Sponsor
- Istituto Scientifico H. San Raffaele
Gastric Cancer
A Study to Evaluate the Efficacy and Safety of Trastuzumab in Combination With Capecitabine and Oxaliplatin as First-line Chemotherapy for Inoperable, Locally Advanced or Recurrent and/or Metastatic Gastric Cancer
Although the overall incidence of gastric cancer has steadily declined in many Western countries during the last few decades, it is still one of the most common tumors in China.
- Trial name
- NCT01364493
- Testing
- Trastuzumab+Capecitabine+Oxaliplatin
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Peking University
Advanced or Inoperable Gastric Cancer
Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer
This study enrolled participants with previously-treated advanced or inoperable gastric cancer who have responded to first line platinum therapy into two treatment arms.
- Trial name
- NCT03427814
- Testing
- Pamiparib
- Where
- 65 sites in United States, Australia and 14 more
- Volunteers
- 136 people
- Sponsor
- BeiGene
Adnexal Tumor of Skin, Merkel Cell Carcinoma
French National Database of Rare Dermatological Cancers
Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, and cutaneous adnexal carcinomas are 3 types of rare skin cancers for which much remains unknown in terms of natural behavior, prognosis…
- Conditions
- Adnexal Tumor of Skin, Merkel Cell Carcinoma, Advanced Basal Cell Carcinoma Requiring Systemic Treatment
- Trial name
- CARADERM (NCT03210935)
- Where
- 34 sites in France
- Volunteers
- 9,000 people
- Sponsor
- University Hospital, Lille
Carcinoma, Non-Small-Cell Lung
Inoperable Non-Squamous NSCLC Stage III/IV: A Randomised Phase II Study With Bevacizumab Plus Erlotinib Or Gemcitabine/Cisplatin Plus Bevacizumab
This study wants to determine the activity of a non chemotherapy first line biological treatment with Erlotinib/Bevacizumab or Gemcitabine-Cisplatin/Bevacizumab in patients with the diagnosis of non-squamous advanced Non Small…
- Trial name
- INNOVATIONS (NCT00536640)
- Testing
- Erlotinib, Bevacizumab, Gemcitabine
- Where
- 37 sites in Germany
- Volunteers
- 224 people
- Sponsor
- Aktion Bronchialkarzinom e.V.
Recurrent Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer
Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of radiation therapy when given together with cisplatin and etoposide in treating patients with non-small cell lung cancer that cannot be removed by surgery.
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
- Trial name
- NCT01411098
- Testing
- 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, cisplatin
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Washington
Mesothelioma
An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma
A clinical study to assess if a new investigational drug is effective in treating malignant mesothelioma, compared to a chemotherapy treatment (Navelbine®).
- Trial name
- NCT00597116
- Testing
- Vinorelbine, Vandetanib
- Where
- 6 sites in Germany, Switzerland
- Volunteers
- 25 people
- Sponsor
- Genzyme, a Sanofi Company
NSCLC, Stage III
SHR-1701 for Consolidation Therapy After Concurrent Chemoradiotherapy in Inoperable Stage III NSCLC
This is a phase II, open-label, single arm study, aiming to investigate the safety and efficacy of SHR-1701 consolidation therapy after concurrent chemoradiotherapy in inoperable stage III non-small-cell lung cancer (NSCLC)
- Trial name
- NCT05177497
- Testing
- SHR-1701
- Volunteers
- 19 people
- Sponsor
- Shanghai Chest Hospital
Inoperable or Recurrent or Metastatic Esophageal Squamous Carcinoma
A Trial to Evaluate the Efficacy of Poziotinib, Pan HER Inhibitor in Recurrent/Metastatic Esophageal Cancer (R/M ESCC)
Esophageal cancer is the sixth most common cause of cancer deaths worldwide. Esophageal adenocarcinoma has become more common in Western countries.
- Trial name
- NCT03770988
- Testing
- Treatment with Poziotinib
- Where
- South Korea
- Volunteers
- 49 people
- Sponsor
- Yonsei University
Non Small Cell Lung Cancer Stage IIIB, Non-Small Cell Carcinoma of Lung, TNM Stage 4
Efficacy, Safety and Pharmacokinetics of BCD-100 (Anti-PD-1) Monotherapy as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (DOMINUS)
International multi-center open-label randomized clinical trial of efficacy, safety and pharmacokinetics of BCD-100 (JSC BIOCAD, Russia) monotherapy compared to docetaxel as second-line therapy of patients with advanced…
- Trial name
- DOMINUS (NCT03288870)
- Testing
- BCD-100, Docetaxel
- Where
- 8 sites in Belarus, Russia
- Volunteers
- 218 people
- Sponsor
- Biocad
Lung Cancer
Percutaneous Cryoablation Peripheral Lung Cancer
This study is focus on percutaneous cryoablation,which was for the treatment of medically inoperable Peripheral lung cancer.The patients who were agreed to attend the study will accept the operation.
- Trial name
- PCPLC (NCT02665390)
- Testing
- Percutaneous cryoablation
- Volunteers
- 30 people
- Sponsor
- Shanghai Chest Hospital
Carcinoma, Non-Small-Cell Lung
Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy
This study uses durvalumab (MEDI 4736), an experimental type of drug made by Astra Zeneca Pharmaceuticals, (limited partnership) LP, which in early studies has shown to possibly reduce the growth of certain types of lung cancer.
- Trial name
- NCT03148327
- Testing
- Durvalumab (MEDI 4736), Radiotherapy
- Where
- 4 sites in United States, Australia
- Volunteers
- 18 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Lung Cancer, Mesothelioma
CryoSpray Ablation(tm)in Malignant Airway Disease to Determine Safety, and Tissue Effect in the Lung (ICE the MAD)
The purpose of this study is to evaluate the safety, and tissue effect of the CryoSpray Ablation(TM) System (CryoSpray Ablation(TM), "CSA" or "cryospray therapy") at multiple centers to treat malignant airway disease in the lung…
- Trial name
- ICEtheMAD (NCT00748085)
- Testing
- CryoSpray Ablation
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- CSA Medical, Inc.
Carcinoma, Hepatocellular, Liver Neoplasms
Tumor Ablation With Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC)
The purpose of this study is to determine whether the Litx™ treatment is safe and effective in treating inoperable hepatocellular carcinoma (HCC).
- Trial name
- NCT00122876
- Testing
- Photodynamic therapy, Talaporfin Sodium
- Where
- 9 sites in Hong Kong, Singapore and 1 more
- Volunteers
- 25 people
- Sponsor
- Light Sciences Oncology
Liver Cancer
A Randomized Double-blind, Placebo-controlled Japanese Phase III Trial of ARQ 197 in Hepatocellular Carcinoma (HCC)
The present clinical trial is aiming to evaluate efficacy of ARQ 197 in patients with hepatocellular carcinoma (HCC), who were resistant or intolerable to one systemic chemotherapy regimen including sorafenib.
- Trial name
- JET-HCC (NCT02029157)
- Testing
- ARQ197
- Where
- Japan
- Volunteers
- 386 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Non-small Cell Lung Cancer
Dose Escalation Trial of Bexmarilimab (FP-1305) Plus Pembrolizumab in Non-Small Cell Lung Cancer
This study enrolls patients with Non-small cell lung cancer and treats them with the investigational drug Bexmarilimab (FP-1305) plus standard of care Pembrolizumab to block Common lymphatic endothelial and vascular endothelial…
- Trial name
- NCT05171062
- Testing
- bexmarilimab (FP-1305), Pembrolizumab
- Where
- United States
- Sponsor
- The University of Texas Health Science Center at San Antonio
Esophageal Squamous Cell Carcinoma, Gastric Carcinoma, Gastroesophageal Junction Carcinoma
BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma
This is a Phase 2, multi-cohort study to investigate safety, PK, and preliminary anti-tumor activity of the monoclonal antibody BGB A317 in combination with standard chemotherapy as first-line treatment.
- Trial name
- NCT03469557
- Testing
- Tislelizumab, Cisplatin, 5-FU
- Where
- 6 sites in China
- Volunteers
- 30 people
- Sponsor
- BeiGene